Back

Efficacy and safety of proprotein covertase subtilisin/kexin type 9 inhibitors among patients with acute coronary syndrome: a meta-analysis of randomized controlled trials

27 August 2022 (16:15 - 17:00)
Organised by:
Congress Presentation Part of: Antithrombotic and anticoagulant therapy Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Samantha Delgado

Saint Lukes Medical Center Global City, Taguig (Philippines)

8 More presentations in this session

Presentation thumbnail
Associations between DAPT score and long-term mortality post PCI
Doctor M. Tan (Melbourne, AU)
Abstract Slides
Presentation thumbnail
Ticagrelor or prasugrel in patients with acute coronary syndrome and high bleeding risk
Doctor S. Lahu (Munich, DE)
Abstract Slides
Presentation thumbnail
Intracoronary thrombolysis facilitated primary percutaneous coronary intervention in ST-segment elevation myocardial infarction patients: an updated meta-analysis of randomized controlled trials
Doctor S. Alexiou (Thessaloniki, GR)
Abstract Slides
Presentation thumbnail
Abbreviated dual antiplatelet therapy after PCI in patients at high bleeding risk: a collaborative meta-analysis of randomized trials
Doctor F. Costa (Malaga, ES)
Abstract Slides
Presentation thumbnail
Perioperative risk and benefit of antiplatelet therapy in patients undergoing non-cardiac surgery within 1 year after percutaneous coronary intervention with second-generation drug-eluting stents.
Doctor S. Lee (Seoul, KR)
Abstract Slides

Access the full session

Session thumbnail
Antithrombotic and anticoagulant therapy

The Event

Event poster

ESC Congress 2022

27 August 2022 16:15 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources